REFERENCES
- Jabs D A, Bartlett J G. AIDS and ophthalmology: a period of transition. Am J Ophthalmol. 1997; 124: 227–233, [PUBMED], [INFOTRIEVE], [CSA]
- Holtzer C D, Jacobson M A, Hadley W K, et al. Decline in the rate of specific opportunistic infections at San Francisco General Hospital. AIDS 1998; 12: 1991–1993
- Palella F J, Delaney K M, Moorman A C, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998; 338: 853–860, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Zegans M E, Walton R C, Holland G N, O'Donnell J J, Jacobson M A, Margolis T P. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol. 1998; 125: 292–300, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Nguyen Q D, Kempen J H, Bolton S G, Dunn J P, Jabs D A. Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis following highly active antiretroviral therapy. Am J Ophthalmol. 2000; 129: 634–639, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Saran B R, Maguire A M, Nichols C, et al. Hypopyon uveitis in patients with acquired immunodeficiency syndrome treated for systemic Mycobacterium avium complex infection with rifabutin. Arch Ophthalmol. 1994; 112: 1159–1165, [PUBMED], [INFOTRIEVE], [CSA]
- Jacobs D S, Piliero P J, Kuperwaser M G, et al. Acute uveitis associated with rifabutin use in patients with human immunodeficiency virus infection. Am J Ophthalmol. 1994; 118: 716–722, [PUBMED], [INFOTRIEVE], [CSA]
- Chu D S, Zaidman G W, Meisler D M, et al. Human immunodeficiency virus-positive patients with posterior intracorneal precipitates. Ophthalmology 2001; 108: 1853–1857, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- O'Connor G R. Ocular sarcoidosis. Trans New Orleans Acad Ophthalmol. 1983; 31: 211–222, [PUBMED], [INFOTRIEVE]
- Smith J A, Mueller B U, Nussenblatt R B, Whitcup S M. Corneal endothelial deposits in children positive for human immunodeficiency virus receiving rifabutin prophylaxis for Mycobacterium avium complex bacteremia. Am J Ophthalmol. 1999; 127: 164–169, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Holland S P, Chang C W, Vagh M, Courtright P for St. Paul's Ocular AIDS Group. Corneal endothelial deposits in patients with HIV infection or AIDS: epidemiologic evidence of the contribution of rifabutin. Can J Ophthalmol. 1999; 34: 204–209, [PUBMED], [INFOTRIEVE], [CSA]
- Walter K A, Coulter V L, Palay D A, et al. Corneal endothelial deposits in patients with cytomegalovirus retinitis. Am J Ophthalmol. 1996; 121: 391–396, [PUBMED], [INFOTRIEVE], [CSA]
- Stewart J A, Reef S E, Pellett P E, et al. Herpesvirus infections in persons infected with human immunodeficiency virus. Clin Infect Dis. 1995; 21: S114–120, (Suppl 1)[PUBMED], [INFOTRIEVE]
- Ashraf F, Cogan D G, Kruth H S. Apolipoprotein A-I and B distribution in the human cornea. Invest Ophthalmol Vis Sci. 1993; 34: 3574–3578, [PUBMED], [INFOTRIEVE], [CSA]
- Rodrigues M M, Kruth H S, Krachmer J H, Willis R. Unesterified cholesterol in Schnyder's corneal crystalline dystrophy. Am J Ophthalmol. 1987; 104: 157–163, [PUBMED], [INFOTRIEVE]
- Kruth H S. Accumulation of unesterified cholesterol in limbal cornea and conjunctiva of rabbits fed a high-cholesterol diet. Detection with filipin. Atherosclerosis 1987; 63: 1–6
- Curran R E, Kenyon K R, Green W R. Pre-Descemet's membrane corneal dystrophy. Am J Ophthalmol. 1974; 77: 711–716, [PUBMED], [INFOTRIEVE]
- Saves M, Raffi F, Capeau J, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2002; 34: 1396–1405, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Heath K V, Hogg R S, Chan K J, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS. 2001; 15: 231–239, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Rakotoambinina B, Medioni J, Rabian C, et al. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor. J Acquir Immune Defic Syndr. 2001; 27: 443–449, [PUBMED], [INFOTRIEVE]
- Liang J S, Distler O, Cooper D A, et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nature Med. 2001; 7: 1327–1331, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Calza L, Manfredi R, Chiodo F. Hyperlipidemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management. Int J Antimicrob Agents. 2003; 22(2)89–99, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lucas G M, Chaisson R E, Moore R D. Survival in an urban HIV-1 clinic in the era of highly active antiretroviral therapy: A 5-year cohort study. J Acquir Immune Defic Syndr. 2003; 33: 321–328, [PUBMED], [INFOTRIEVE]
- Dube M, Fenton M. Lipid abnormalities. Clin Infect Dis. 2003; 36: S79–S83, [PUBMED], [INFOTRIEVE], [CROSSREF]